“增肌減脂”重磅藥有望?來凱醫藥(2105.HK)打好單靶點藥物+雙靶點抗體"激活素管線組合拳"
減肥藥巨頭禮來(LLY.US)的比馬格魯單抗的II期臨牀試驗結果將在近期內揭曉,倍受制藥界關注。業界都期待在這個領域能夠誕生下一個重磅大藥,造福全球的肥胖症患者。比馬格魯單抗是對ActRIIA和ActRIIB都有拮抗作用的雙靶點抗體,業內認為,要想找到這兩個亞型之間最為理想的協同工作狀態,必須有高特異性的單靶點藥物進行不同組合的優化研究。對此,生物技術公司來凱醫藥(2105.HK)的"激活素管線組合拳"或有可能找到兩個亞型之間更為理想的協同效應,為其後續藥的開發拓展出足夠的空間。臨牀前研究結果顯示,在肥胖(DIO)小鼠模型的三週試驗中,來凱醫藥自主研發的針對ActRIIA的單克隆體LAE102作為單藥有增肌減脂效果,當跟司美格魯肽聯用時,可以看到更多脂肪的減少以及肌肉保護作用,可能足以彌補司美格魯肽導致肌肉流失的不足。來凱醫藥的"激活素管線組合拳"通過多種靈活組合,在不同的方向上進行優化,找到最佳組合,滿足增肌減脂的臨牀需求。此外,"組合拳"完全有可能獲得干預調控迴路更優的療效與安全比,還有可能擴展到其他更多的疾病適應症,比如肌肉缺少適應症、癌症以及肺動脈高壓等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.